These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32233322)

  • 21. Hypereosinophilic syndromes.
    Roufosse FE; Goldman M; Cogan E
    Orphanet J Rare Dis; 2007 Sep; 2():37. PubMed ID: 17848188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hypereosinophilic syndrome--recent developments in diagnosis and treatment].
    Hellmich B; Holl-Ulrich K; Gross WL
    Dtsch Med Wochenschr; 2007 Sep; 132(37):1892-6. PubMed ID: 17823882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
    Li B; Zhang GS; Dai CW; Pei MF
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
    Yamada Y; Cancelas JA; Rothenberg ME
    Int Arch Allergy Immunol; 2009; 149 Suppl 1():102-7. PubMed ID: 19494514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy].
    Sekkach Y; Mekouar F; Jira M; Elqatni M; Elomri N; Fatihi J; Badaoui M; Hammi S; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D
    Ann Pharm Fr; 2011 Sep; 69(5):277-81. PubMed ID: 21924129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hematological disorders and hypereosinophilias].
    Malfuson JV; Fagot T; Konopacki J; Mangouka L; Souleau B; de Revel T
    Rev Med Interne; 2009 Apr; 30(4):322-30. PubMed ID: 19201511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.
    Stone RM; Gilliland DG; Klion AD
    Semin Oncol; 2004 Apr; 31(2 Suppl 6):12-7. PubMed ID: 15175999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
    Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
    Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cough in hypereosinophilic syndrome: case report and literature review.
    Xie J; Zhang J; Zhang X; Zhang Q; Chung KF; Wang C; Lai K
    BMC Pulm Med; 2020 Apr; 20(1):90. PubMed ID: 32293378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes.
    Groh M; Rohmer J; Etienne N; Abou Chahla W; Baudet A; Chan Hew Wai A; Chenivesse C; Clisson Rusek I; Cottin V; Decamp M; De Groote P; Delahousse F; Duployez N; Faguer S; Gottrand F; Huang F; Leblanc T; Magnan A; Martin T; Mortuaire G; Néel A; Paris L; Petit A; Rossignol J; Schleinitz N; Soret-Dulphy J; Staumont-Salle D; Terrier B; Terriou L; Viallard JF; Lefèvre G; Kahn JE
    Orphanet J Rare Dis; 2023 Apr; 18(1):100. PubMed ID: 37122022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New insights into hypereosinophilic syndromes].
    Bletry O; Kahn JE; Ackermann F; Charles P; Legrand F
    Bull Acad Natl Med; 2010 Mar; 194(3):547-59; discussion 559-60. PubMed ID: 21171248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
    Antoniu SA
    Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biologics and Hypereosinophilic Syndromes: Knowledge Gaps and Controversies.
    Kuang FL; Khoury P; Weller PF; Wechsler ME; Klion AD
    J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2666-2671. PubMed ID: 37507068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical management of the hypereosinophilic syndromes.
    Cogan E; Roufosse F
    Expert Rev Hematol; 2012 Jun; 5(3):275-89; quiz 290. PubMed ID: 22780208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants.
    Roufosse F; Goldman M; Cogan E
    Semin Respir Crit Care Med; 2006 Apr; 27(2):158-70. PubMed ID: 16612767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia.
    Yamada Y; Rothenberg ME; Cancelas JA
    Transl Oncogenomics; 2006; 1():53-63. PubMed ID: 23662039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB; Sheikh J; Singh A
    Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?
    Iurlo A; Cattaneo D
    Blood Rev; 2023 Mar; 58():101014. PubMed ID: 36153195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The Lymphoid Variant of HES (L-HES) as Differential Diagnose of Severe Asthma in Childhood].
    Leu T; Rauthe S; Wirth C; Simon HU; Kunzmann V; Hebestreit H; Kunzmann S
    Klin Padiatr; 2016 Nov; 228(6-07):319-324. PubMed ID: 27846662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.